<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04230629</url>
  </required_header>
  <id_info>
    <org_study_id>2060/2019</org_study_id>
    <nct_id>NCT04230629</nct_id>
  </id_info>
  <brief_title>Evaluation of Physiological Responses at the Anterior Surface of Two (Hydrophobic Acrylic) Intraocular Lens Models</brief_title>
  <official_title>Evaluation of Physiological Responses at the Anterior Surface of Two (Hydrophobic Acrylic) Intraocular Lens Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the day of surgery, the the eye with astigmatism of at least 0.75dpt receives a Vivinex
      XY1A , HOYA Surgical Optics GmbH and the second eye to be operated receives an XY1, HOYA
      Surgical Optics GmbH.

      A complete biomicroscopic examination and visual acuity testing using autorefractometer, will
      be performed 1 week (7-14days), 6 weeks (30-60days) and 5 month (4-6months) postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of FBGC (foreign body giant cells) (slitlamp examination)</measure>
    <time_frame>5 months</time_frame>
    <description>The number of foreign body giant cells on the IOLs will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Monocytes (slitlamp examination)</measure>
    <time_frame>5 months</time_frame>
    <description>The number of monocytes on the IOLs will be assessed. The following classification will be used: + = fewer than 10 cells/mm2; ++ = 10 to 25 cells/mm2; +++ = more than 25 cells/mm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCO Score (slitlamp examination)</measure>
    <time_frame>5 months</time_frame>
    <description>Incidence and development of posterior capsular opacification will be subjectively graded: 0-10 (0= no PCO, 10= maximum PCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of Anterior Fibrosis (slitlamp examination)</measure>
    <time_frame>5 months</time_frame>
    <description>Grade of anterior fibrosis assessed subjectively at the slitlamp (grade 0=no fibrosis, grade 3=maximum fibrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber reaction (slitlamp examination)</measure>
    <time_frame>5 months</time_frame>
    <description>Incidence of cells and tyndall in the anterior chamber (ratet as - to +++ respectively)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Age Related Cataracts</condition>
  <arm_group>
    <arm_group_label>Vivinex XY1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of an intraocular lens Hoya Vivinex XY1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vivinex XY1A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of an intraocular lens Hoya Vivinex XY1A</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivinex XY1</intervention_name>
    <description>Implantation of an intraocular lens Hoya Vivinex XY1</description>
    <arm_group_label>Vivinex XY1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivinex XY1A</intervention_name>
    <description>Implantation of an intraocular lens Hoya Vivinex XY1A</description>
    <arm_group_label>Vivinex XY1A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral age-related cataract for which phacoemulsification extraction and posterior
             IOL implantation is planned

          -  Age 40 and older

          -  Astigmatism of at least 0.75Diopters in one eye

          -  Normal findings in medical history and physical examination unless the investigator
             considers an abnormality to be clinically irrelevant

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Pseudoexfoliation syndrome

          -  Systemical anticoagulation

          -  Antiphlogistic therapy

          -  Antiglaucomatosa

          -  Uncontrolled systemic or ocular disease

          -  Preceding ocular surgery or trauma

          -  Intraoperative complications

          -  Pregnancy/Nursing

          -  Concurrently participating in any other clinical trial or if they have participated in
             any other clinical trial during the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rupert Menapace</last_name>
    <phone>0140400</phone>
    <phone_ext>66300</phone_ext>
    <email>rupert.menapace@meduniwien.ac.at</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Menapace</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

